Pharmaceutical

Cercare Medical Showcases Breakthrough CBCT Perfusion Technology at RSNA 2025

Bringing Advanced Perfusion Imaging Into the Angio Suite to Transform Stroke and Oncology Care CHICAGO, IL / ACCESS Newswire /…

1 week ago

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol “GRDX”

BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that…

1 week ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and…

1 week ago

Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 28,…

1 week ago

Boehringer Ingelheim announces appointment to Board of Managing Directors

Harsha Deshmukh Harsha Deshmukh Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for…

1 week ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ETNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG…

1 week ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,…

1 week ago

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),…

1 week ago

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

1 week ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…

1 week ago